eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | adenocarcinoma of esophagus |
| Symptom | C0004763|barrett\'s esophagus |
| Sentences | 31 |
| PubMedID- 23714382 | Background & aims: recent population-based studies have shown a low risk of esophageal adenocarcinoma (eac) in patients with nondysplastic barrett's esophagus (ndbe). |
| PubMedID- 23338150 | Therefore, telomerase inhibitors may exhibit high potency in the treatment of esophageal adenocarcinoma arising from barrett's esophagus. |
| PubMedID- 22302717 | There is a critical need to identify molecular markers that can reliably aid in stratifying esophageal adenocarcinoma (eac) risk in patients with barrett's esophagus. |
| PubMedID- 26233550 | Serum 25-hydroxyvitamin d levels and the risk of dysplasia and esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 20397052 | Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 23617672 | It is often difficult to accurately delineate the borders and extent of early-stage esophageal adenocarcinoma in patients with barrett's esophagus using conventional white light endoscopy. |
| PubMedID- 22626608 | Background & aims: radiofrequency ablation (rfa) reduces the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be) with high-grade dysplasia (hgd), but its effects in patients without dysplasia are debatable. |
| PubMedID- 21345220 | Investigation of the expression of an intestinal stem cell marker in esophageal adenocarcinomas (eac) with and without barrett's esophagus (be), with respect to a cancer stem cell (csc) hypothesis. |
| PubMedID- 24681073 | Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with barrett's esophagus. |
| PubMedID- 26208896 | Background & aims: statins have been reported to protect against esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be). |
| PubMedID- 20946664 | There were n = 41 esophageal adenocarcinomas (eac) with associated barrett's esophagus (be), n = 19 eac without be and n = 10 esophageal squamous-cell carcinomas of the esophagus (which were intended to serve as positive control for mmp-1 expression), and n = 18 barrett's biopsies without intraepithelial neoplasia or invasive carcinoma which were derived from patients with gastroesophageal reflux disease (gerd). |
| PubMedID- 22272378 | found a correlation between cox2 expression and tp53 wild-type status in esophageal adenocarcinoma with barrett's esophagus as a precursor lesion, but not in scc, providing evidence that the participation of p53 in the regulation of cox2 expression in cancer may be dependent on tumor histology. |
| PubMedID- 22443641 | Previously, the risk of progression to esophageal adenocarcinoma in patients with barrett's esophagus was thought to be approximately 1%. |
| PubMedID- 25071359 | Lifetime risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 19850156 | Risk of esophageal adenocarcinoma and mortality in patients with barrett's esophagus: a systematic review and meta-analysis. |
| PubMedID- 21115135 | The incidence of esophageal adenocarcinoma among patients with nondysplastic barrett's esophagus has been overestimated. |
| PubMedID- 24867156 | Recent findings: rfa is well tolerated and efficacious in most but not all barrett's esophagus patients with dysplasia and esophageal adenocarcinoma (eac). |
| PubMedID- 26202380 | Overexpression of cd55 from barrett's esophagus is associated with esophageal adenocarcinoma risk. |
| PubMedID- 20188100 | However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (eac) in patients with existing barrett's esophagus (be) is unclear. |
| PubMedID- 25843080 | Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with barrett's esophagus(gut 2014;63:1229-1237). |
| PubMedID- 21375764 | In contrast with the esophageal adenocarcinoma arising from barrett's esophagus in western countries, the major phenotype in the asia-pacific region is esophageal squamous cell carcinoma (escc) . |
| PubMedID- 26068095 | We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac) in patients with barrett's esophagus by testing nonneoplastic bim. |
| PubMedID- 21698030 | The majority of lower esophageal adenocarcinomas appear in patients with barrett's esophagus (be), a premalignant condition in which the normal squamous epithelium is replaced by metaplastic columnar epithelium. |
| PubMedID- 22241250 | Use of statin medications and risk of esophageal adenocarcinoma in persons with barrett's esophagus. |
| PubMedID- 21309910 | Dysplasia and esophageal adenocarcinoma may arise in patients with barrett's esophagus after fundoplication esophageal ph monitoring showing no acid in esophagus. |
| PubMedID- 21820152 | The progression of intestinal metaplasia to esophageal adenocarcinoma in patients with barrett's esophagus is partly driven by chromosomal alterations that activate oncogenes and inactivate tumor suppressor genes. |
| PubMedID- 26426603 | Cost-effectiveness decision tree model of endoscopic surveillance for esophageal adenocarcinoma among patients with definite barrett's esophagus. |
| PubMedID- 24795040 | Background: proton pump inhibitors (ppis) may reduce the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus. |
| PubMedID- 23243384 | For upper gi tract pathology i-scan assisted in diagnosis or therapy of barrett's esophagus with dysplasia, esophageal adenocarcinoma, hsv esophagitis, gastric malt lymphoma, gastric antral intestinal metaplasia with dysplasia, duodenal follicular lymphoma, and a flat duodenal adenoma. |
| PubMedID- 24651385 | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis. |
| PubMedID- 22796132 | Background& aims: proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with barrett's esophagus (be), but there are limited data from clinical trials to support this concept. |
Page: 1